Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEXFLAP: Dexmedetomidine in Reconstructive Microsurgery for Cancer Patients
NCT06993740Completed
- Sponsor
- Dharmais Cancer Hospital
- Start
- Jun 2025
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial comparing Placebo Group with Dexmedetomidine Group (2 arms). Primary endpoint: Flap Viability Score. Started Jun 2025; status: completed.
02
Drugs
dexmedetomidine
Beyond the preview
Go deeper on NCT06993740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06993740.